The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia

Haematologica. 2015 Jan;100(1):91-9. doi: 10.3324/haematol.2014.113142. Epub 2014 Oct 3.

Abstract

T-cell large granular lymphocytic leukemia and chronic lymphoproliferative disorder of natural killer cells are intriguing entities between benign and malignant lymphoproliferation. The molecular pathogenesis has partly been uncovered by the recent discovery of somatic activating STAT3 and STAT5b mutations. Here we show that 43% (75/174) of patients with T-cell large granular lymphocytic leukemia and 18% (7/39) with chronic lymphoproliferative disorder of natural killer cells harbor STAT3 mutations when analyzed by quantitative deep amplicon sequencing. Surprisingly, 17% of the STAT3-mutated patients carried multiple STAT3 mutations, which were located in different lymphocyte clones. The size of the mutated clone correlated well with the degree of clonal expansion of the T-cell repertoire analyzed by T-cell receptor beta chain deep sequencing. The analysis of sequential samples suggested that current immunosuppressive therapy is not able to reduce the level of the mutated clone in most cases, thus warranting the search for novel targeted therapies. Our findings imply that the clonal landscape of large granular lymphocytic leukemia is more complex than considered before, and a substantial number of patients have multiple lymphocyte subclones harboring different STAT3 mutations, thus mimicking the situation in acute leukemia.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Arthritis, Rheumatoid / genetics*
  • Biomarkers / analysis*
  • Clonal Evolution / genetics*
  • Female
  • Follow-Up Studies
  • High-Throughput Nucleotide Sequencing / methods
  • Humans
  • Killer Cells, Natural / drug effects
  • Killer Cells, Natural / metabolism
  • Killer Cells, Natural / pathology
  • Leukemia, Large Granular Lymphocytic / drug therapy
  • Leukemia, Large Granular Lymphocytic / genetics*
  • Leukemia, Large Granular Lymphocytic / pathology
  • Male
  • Middle Aged
  • Mutation / genetics*
  • Neoplasm Staging
  • Prognosis
  • Receptors, Antigen, T-Cell, alpha-beta / genetics
  • STAT3 Transcription Factor / genetics*
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / metabolism
  • T-Lymphocytes / pathology*
  • Young Adult

Substances

  • Biomarkers
  • Receptors, Antigen, T-Cell, alpha-beta
  • STAT3 Transcription Factor